Li Zhu-Jun, Wang Li-Quan, Li Yun-Zhu, Wang Chen-Yu, Huang Jiu-Zuo, Yu Nan-Ze, Long Xiao
Department of Plastic and Reconstructive Surgery, Peking Union Medical College Hospital of Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China.
World J Stem Cells. 2021 Nov 26;13(11):1747-1761. doi: 10.4252/wjsc.v13.i11.1747.
Fibrosis is the hyperactivation of fibroblasts that results in excessive accumulation of extracellular matrix, which is involved in numerous pathological changes and diseases. Adipose-derived stem cells (ASCs) are promising seed cells for regenerative medicine due to their bountiful source, low immunogenicity and lack of ethical issues. Their anti-fibrosis, immunomodulation, angiogenesis and other therapeutic effects have made them suitable for treating fibrosis-related diseases. Here, we review the literature on ASCs treating fibrosis, elaborate and discuss their mechanisms of action, changes in disease environment, ways to enhance therapeutic effects, as well as current preclinical and clinical studies, in order to provide a general picture of ASCs treating fibrotic diseases.
纤维化是成纤维细胞的过度活化，导致细胞外基质过度积累，这与众多病理变化和疾病相关。脂肪来源干细胞（ASC）因其来源丰富、免疫原性低且不存在伦理问题，是再生医学中很有前景的种子细胞。它们的抗纤维化、免疫调节、血管生成及其他治疗作用使其适用于治疗纤维化相关疾病。在此，我们综述了关于ASC治疗纤维化的文献，阐述并讨论其作用机制、疾病环境变化、增强治疗效果的方法以及当前的临床前和临床研究，以便全面了解ASC治疗纤维化疾病的情况。
